InvestorsHub Logo

DoTheRightThing

05/08/23 10:35 AM

#414260 RE: bas2020 #414252

So because some loser writes hit pieces, Anavex's reaction is to just take their ball and go home? Meanwhile all of you will vote for another round of raises for the execs while they do absolutely nothing. If Missling was a fighter, he would have all hands on deck ready to respond immediately to hit pieces upon data releases. If it was me, I'd have my team meet beforehand trying to anticipate what holes the detractors will point out and have responses prepared in advance. You don't just sit on your hands while your company's rep gets trashed, and especially in biotech, for a small company to breakthrough, it is a battle. You can't just sit around waiting for someone to give it to you, you have to take it.

tredenwater2

05/08/23 11:10 AM

#414266 RE: bas2020 #414252

“ It's worse than that... anything that Missling announces, regardless of how positive or confirmatory, will be met with coordinated selling (naked shorting).”

Thats because he hasnt payed the entrance fee yet to the casino in secondary shares. If you want to play in their “game” using their money then you need need to pay to play. Funny part is we most likely would still he where we are currently at MC wise but with a few spikes from “selloffs” by the HF’s only to line back up to the trough of to reload.

Historic and unprecedented ride to marketization by a baby bio imo. Should make for an interesting movie someday, especially as we get closer.

As far as his “ commercialization” comment, I cant help but continue to wonder how much AU will play a role in this. They HAVE to be seeing unprecedented results in Rett Syndrome, Parkinson’s Disease Dementia, and Alzheimer’s both in trial participants and OLE’s. Will Spain/Europe join in? Dr. Missling is many things but one thing he isnt is dumb. He knows we need revenue to break the backs of this MC grid lock. While everyone else is focusing on what ifs, data whereabouts, and new trial wonderments he is racing to market for revenue with current and near term results in hand. Oh, and dont forget about those ever so important early partners like Rett Syndrome. Org, RAM, and all those at the different UC extensions like Dr. Randi Hagerman at UC Davis etc. When we go to market overseas there will be an uproar for our drug here in the US. Hopefully by that time we have submitted our NDA and just about pushing the Fda a bit more over the line for US approval.